SLS - SELLAS Life Sciences Group Inc
IEX Last Trade
1.29
-0.010 -0.775%
Share volume: 535,683
Last Updated: Fri 30 Aug 2024 09:59:53 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.30
-0.01
-0.77%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | |
|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | |
| Report Date | 2022-05-12 | 2022-08-11 | 2022-11-14 | 2023-03-16 | |
| Total revenue | 1.000 M | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 100.000 K | 0.000 | 0.000 | 0.000 | |
| Gross profit | 900.000 K | 0.000 | 0.000 | 0.000 | |
| -100.00% | nan% | nan% | |||
| Operating expenses | 7.635 M | 8.623 M | 7.146 M | 9.446 M | |
| Selling general and admin | 3.024 M | 3.094 M | 2.864 M | 3.600 M | |
| Research and development | 4.611 M | 5.529 M | 4.282 M | 5.846 M | |
| Total expenses | 7.735 M | 8.623 M | 7.146 M | 9.446 M | |
| 11.48% | -17.13% | 32.19% | |||
| Operating income | -6.735 M | -8.623 M | -7.146 M | -9.446 M | |
| Ebit | -6.735 M | -8.623 M | -7.146 M | -9.446 M | |
| Pretax income | -16.744 M | -8.414 M | -7.022 M | -9.121 M | |
| -49.75% | -16.54% | 29.89% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -16.744 M | -8.414 M | -7.022 M | -9.121 M | |
| 49.75% | 16.54% | -29.89% | |||
| Net income | -16.744 M | -8.414 M | -7.022 M | -9.121 M | |
| 49.75% | 16.54% | -29.89% |